SYNGULON

Syngulon is a synthetic biology startup developing original genetic technologies. 

Syngulon’s platform technologies are based on bacteriocins, natural antimicrobial peptides. They are bactericidal (killing certain micro-organisms) or bacteriostatic (inhibiting the growth of certain micro-organisms). Bacteriocins are ribosomally-produced, genetically encoded by a wide variety of microorganisms. They were forgotten with the exception of Nisin (GRAS/E234) used as food preservative. The antibiotics currently used are chemical compounds. 

Syngulon’s original and disruptive genetic technologies using bacteriocins are solving 3 problems: 

1. antibiotic-free technologies for production in a fermentation process (Solar Impulse Efficient Solution Label since May 2021); key markets are human and animal biopharma, enzymes and industrial biotech 

2. prevention of contamination by using bacteriocins that target the bacteria having a negative effect on the production process; key markets are ethanol, cooling towers, feed, animal health 

3. human therapeutic applications of bacteriocins as alternative or complement to antibiotics in the context of (1) cancer, (2) microbiome modulation, (3) AntiMicrobial Resistance AMR; market is human pharma 

Syngulon has the largest collection of bacteriocins (PARAGEN with >500) and has currently 11 families of patents (3 co-owned with universities), with already 19 issued Patents (USA #9, EU, China #3, Brazil #2, Japan #2, India and Korea). 

The Business model of Syngulon is the licensing its technologies with a mix of issue fee/milestones/royalties: 

1. for the antibiotic-free technologies, non-exclusive licensing with service for plasmid conversion 

2. for the prevention of contamination, services are provided for the customization of the bacteriocin cocktails before the licensing that can be exclusive for specific bacteriocins and/or field of use 

3. for human pharma, the final products/processes will be out-licensed on an exclusive base.

Syngulon is working as a “Startup in the Labs” working closely with academic partners (e.g. UCLouvain, ULB, KU Leuven in Belgium / Imperial College, UCL in London, UK / Universidad Complutense Madrid, Spain).